Release date:2016-05-13  Release:


Professor of Pharmacy

Director of Department of Marine Pharmacy

School of Life Science and Technology

Phone: 86-25-83271007

Email: 13913925346@126.com

Research Summary

Ms. Hanmei Xu, professor of China Pharmaceutical University, supervisor of PH.D. students, head of the department of marine pharmacy in the college of life science and biotechnology, head of the engineering research center of peptide drug discovery and development of China Pharmaceutical University. She has the experience of innovative peptide drug research and development for a long time and got the clinical approval for Antiangiotide, which is a class 1.1 chemical new drug in China. Currently, she is mainly engaged in innovation peptide drug design and discovery research and immunotherapy for cancer. Several innovative peptides such as anti-tumor, anti-rheumatoid and pulmonary fibrosis are being studied in pre-clinical stage. In recent years, she and her group have been founded byseveral national project and enterprise financing, more than 70 articles have been published, 35 invention patents have been applied.


1998.09-2001.07   Ph.D., Pharmacy, China Pharmaceutical University, China

1995.09-1998.07    M.Sc., Genetics, Yunnan Agricultural University, China

1983.09-1987.07  B.Sc., Inner Mongolia University for Nationalities, China

Work Experience

2014.11--Present   ProfessorDirector of Marine Pharmacy,College of Life Science and Technology, China Pharmaceutical University , China

2012.10-2014.11 Post Doctor, State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, China

Awards and Group Memberships

National innovation and entrepreneurial talent (2015)

Nanjing science and technology entrepreneurs (2014)

Jiangsu provincial medical science and Technology Award (2014)

Nanjing leading talent (2012)

Director of three Science Society

Publications – main publications

1. C.Lin, H. Xu*. Novel perspectives of long noncoding RNAs in esophageal carcinoma. Carcinogenesis. (accepted for publication)

2. C. Zhao, S. Setrerrahmane, H. Xu*. Enrichment and characterization of cancer stem cells from a human non-small cell lung cancer cell line, Oncol Rep,  2015(34): 2126-2132. (DOI:10.3892/or.2015.4163)

3. Zheng Qiu, Fengguo Zhang, Chengxin Gong, Hanmei Xu*, Jialiang Hu*. Fusion peptides CPU1 and CPU2 inhibit matrix metalloproteinases and protect mice from endotoxin shock within a strict time window. Inflammation. 2015, 38: 2092-2104.

4. Jialiang Hu#, Tao Cheng#, Lijun Zhang, Beicheng Sun, Lei Deng, Hanmei Xu*. An anti-tumor peptide AP25 decreased cyclin D1 expression and inhibited MGC-803 proliferation via signal transduction pathways with p-ERK, Src, JNK and PI3K as key enzymes. Molecular Medicine Reports. 2015, 12(3): 4396-402.

5. Zheng Qiu, Jianghai Chen, Hanmei Xu, Philippe E. Van den Steen, Ghislain Opdenakker, Min Wang* and Jialiang Hu*. Inhibition of neutrophil collagenase/MMP-8 and gelatinase B/MMP-9 and protection against endotoxin shock. Journal of Immunology Research. 2014.

6. X. Xu, S. Ren, X. Chen, J. Ge, Z. Xu, H. Huang, H. Sun, Y. Gu, T. Zhou, J. Li*, H. Xu*. Generation of hepatitis B virus preS2-S antigen in Hansenula polymorpha. Virologica Sinica, 2014, 29(6): 4003-409.

7. Jialiang Hu, Ming Yan, Chunyan Pu, Jingjing Wang, Philippe E. Van den steen, GhislainOpdenakker, Hanmei Xu*. Chemically synthesized matrix metalloproteinase- and angiogenesis-inhibiting peptides as anticancer agents. Anti-cancer Reagents ME. 2014, 14(3): 483-94.

8. Shen Hong, Han Haibing, Hu Jialiang, Zhang Xiaojuan, Wang jingjing, Wang Wenjing, Nie Caihui, Xu Hanmei*. PEGylated HM-3 presents anti-rheumatic bioactivity by inhibiting angiogenesis and inflammation. J. Mater. Chem. B, 2014, 2: 800-813.

9. Dongqing Yuan, Hong Shen, Songtao Yuan, Xiaoyi Liu, Xin Xia, Ping Xie, Weiguang Li, Jialiang Hu, Qinghuai Liu*, Hanmei Xu*. Pharmacokinetics of HM-3 after intravitreal administration in mice. Current Eye Research, 2014, 39(8): 837-44.

10. Zheng Qiu, Jialiang Hu, HanmeiXu*, Wenjing Wang, Chunyan Pu, Xiang Wang. Generation of anti-tumor peptides by connection of matrix metalloproteinase-9 peptide inhibitor to an endostatin fragment. Anti-Cancer Drugs.2013, 24: 677-689.

11. Yongbing Li, Hanmei Xu*, Jialiang Hu, Fengguo Zhang, Zhengdong Liu, Chi Zhang, YongjingYang, Chunyan Pu, Linqiu Huang, XinWen. Quantitative Analysis and Pharmacokinetics Study of Integrin Antagonist AP25 in Rat Plasma. Protein Pept Lett. 2013, 20(5): 584-90.

12. Chunyan Pu, HanmeiXu*, Jialiang Hu, Zheng Heng, Xiaofeng Huang, Zhang Chi; Yongjing Yang, Yongbing Li, RGD position has effect on anti-angiogenic activity of RGD modified endostation derived synthetic polypeptides. Anti-cancer drugs. 2012, 12: 788- 802.

13. Li Pan1, Jialiang Hu1, Wenjing Wang1, Xiaojuan Zhang1, Jin Wei1, Zhendong Liu1, Yihua Zhang2* and Hanmei Xu1*. Molecular Mechanisms of (R,R) ZX-5 on NO Synthesis and Its Anti-Angiogenic Effect. International Journal of Molecular Sciences. 2012,13: 2717-2726

14. Liu Zhendong, Li Weiguang, Xu Hanmei*, Huang Xiaofeng, Pan Li, Ren Yinling, Yang Yongjing, Li Yongbing, Pu Chunyan, Zhang Chi. In vivo pharmacokinetics, immunogenicity and mechanism of PEGylated anti-tumor polypeptide. Current Pharmaceutical Design. 2012, 18(12): 1655-1662

15. Guoqiu Wu, Xuepeng Deng,Pengpeng Wu, Zilong Shen, Hanmei Xu*, Subacute toxicity of antimicrobial peptide S-thanatin in ICR mice. Peptides, 2012, 36(1): 109-13

16. Hanmei Xu*, Li Pan, Yinling Ren , et al.An RGD-Modified Angiogenesis Inhibitor HM-3 Dose: Dual Function during Cancer Treatment. Bioconjugate Chem, 2011, 22(7): 1386–1393

17. Zhendong Liu, Yinling Ren, Li Pan and Han-Mei Xu*, In Vivo Anti-Tumor Activity of Polypeptide HM-3 Modified by Different Polyethylene Glycols (PEG). Int. J. Mol. Sci. 2011,12(4),2650-2663.

18. Guoqiu Wu, Xuepeng Deng , Hanmei Xu*, et al. Application of immobilized thrombin for production of S-thanatin expressed in Escherichia coli. Appl Microbiol Biotechnol. 2011,92(1):85-93.

19. Han-Mei Xu, Jin Wei, Zilong Shen1*, et al. The Mechanism of (R, R) ZX-5 Promoting Choroidal Blood Flow and Increasing NO Release.Int. J. Mol. Sci. 2010, 11(9): 3323-3333.

20. Yumei Zhang, Runting Yin, Ruirui Jiang, Enhu Yang, Hanmei Xu*, Ninghua Tan. A New Abietane Diterpene from Glyptostrobus pensilis. Fitoterapia, 2010,81(8): 1202-4.

21. Beili Zhu, Han-Mei Xu*, Liming zhao, et al. Site-specific modification of antiangiogenesis peptide HM-3 by polyethylene glycol molecular weight of 20 kDa , Journal of Biochemistry, 2010,148(3): 341-347.

22. RuntingYin, TaoXi and Han-MeiXu*, et al. Effect of RGD-4C Position is More Important Than Disulfide Bonds on Antiangiogenic Activity of RGD-4C Modified Endostatin Derived Synthetic Polypeptide. Bioconjugate chemistry, 2010,21(7):1142-7.

23. Zhou K, Zheng XQ, Xu HM* , et al. Studies of Poly(ethylene glycol) Modification of HM-3 Polypeptides, bioconjugate chemistry, 2009, 20(5): 932-936